Desmopressin is a synthetic version of vasopressin, the antidiuretic hormone the body uses to control how much water the kidneys hold onto. Chemists built it by making two changes to natural arginine vasopressin: removing an amino group at position 1 and swapping the L-arginine at position 8 for its D-form. That is where its older name comes from, 1-deamino-8-D-arginine vasopressin, usually shortened to DDAVP. The redesign matters because it strips away most of vasopressin's blood-pressure effect while keeping, and extending, the water-retaining action (DrugBank DB00035).
Unlike most peptides this site covers, desmopressin is an old, approved prescription drug with decades of clinical use behind it. It is not a research chemical.
How it works
Desmopressin is a selective agonist of the vasopressin V2 receptor. Those receptors sit in the collecting ducts of the kidney. When desmopressin binds, it triggers a cAMP signal that moves aquaporin-2 water channels into the cell membrane, so more water is reabsorbed and urine becomes more concentrated. Its high selectivity for V2 over V1 receptors is the point of the molecule: V1 activation is what drives vasoconstriction and raises blood pressure, and desmopressin largely avoids it (StatPearls / NCBI Bookshelf).
There is a second, separate effect. V2 stimulation also prompts cells lining the blood vessels to release stored von Willebrand factor and factor VIII from Weibel-Palade bodies. Both are clotting proteins, so a dose of desmopressin can give a short-lived boost to the blood's ability to clot (StatPearls / NCBI Bookshelf).
What it's approved for
FDA-approved uses span both of those mechanisms:
- Central diabetes insipidus — replacing the antidiuretic hormone the body fails to make.
- Primary nocturnal enuresis — bedwetting in children.
- Mild-to-moderate hemophilia A (factor VIII levels above about 5%) and type 1 von Willebrand disease, to maintain hemostasis around surgery or after injury.
It comes as an injection, a nasal spray, and oral or sublingual tablets (StatPearls / NCBI Bookshelf). A separate point on nocturia: dedicated low-dose oral and sublingual products for nighttime urination tied to nocturnal polyuria are approved in many countries, and the U.S. has approved specific nocturia formulations, though older general desmopressin products were not labeled for that use (Medscape drug reference).
The main safety concern
Because the drug makes the kidneys hold water, the dominant risk is hyponatremia — sodium in the blood dropping too low, which in severe cases can cause seizures. Every approved label carries this warning regardless of formulation, and fluid intake is usually restricted while it is in use (StatPearls / NCBI Bookshelf). This article is not medical or dosing advice; desmopressin is a prescription medicine and any use belongs with a clinician.
Status in sport
Desmopressin is banned by WADA. It appears in category S5, Diuretics and Masking Agents, because shifting plasma volume can dilute or otherwise mask other prohibited substances in a doping sample. It sits in that section alongside plasma volume expanders (drugs.com WADA S5 list).
A note for buyers
Desmopressin is a regulated pharmaceutical dispensed by pharmacies, not a gray-market peptide. If you encounter it sold as a "research" powder, the usual cautions apply: material offered outside the regulated supply chain carries no guarantee of identity, purity, or correct peptide content, and a third-party certificate of analysis covering identity and purity is the minimum a careful buyer would want to see. peptideone runs no tests of its own and sells nothing; we aggregate public facts and what independent raters report.